Cargando…
Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study
BACKGROUND: Cyclic vomiting syndrome (CVS), which is defined by recurrent stereotypical episodes of nausea and vomiting, is a relatively-common disabling condition that is associated with migraine headache and mitochondrial dysfunction. Co-enzyme Q10 (Co-Q) is a nutritional supplement that has demon...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825193/ https://www.ncbi.nlm.nih.gov/pubmed/20109231 http://dx.doi.org/10.1186/1471-2377-10-10 |
_version_ | 1782177790200643584 |
---|---|
author | Boles, Richard G Lovett-Barr, Mary R Preston, Amy Li, B UK Adams, Kathleen |
author_facet | Boles, Richard G Lovett-Barr, Mary R Preston, Amy Li, B UK Adams, Kathleen |
author_sort | Boles, Richard G |
collection | PubMed |
description | BACKGROUND: Cyclic vomiting syndrome (CVS), which is defined by recurrent stereotypical episodes of nausea and vomiting, is a relatively-common disabling condition that is associated with migraine headache and mitochondrial dysfunction. Co-enzyme Q10 (Co-Q) is a nutritional supplement that has demonstrated efficacy in pediatric and adult migraine. It is increasingly used in CVS despite the complete lack of studies to demonstrate its value in treatment METHODS: Using an Internet-based survey filled out by subjects with CVS or their parents, the efficacy, tolerability and subject satisfaction in CVS prophylaxis were queried. Subjects taking Co-Q (22 subjects) were compared against those taking amitriptyline (162 subjects), which is the general standard-of-care. RESULTS: Subjects/parents reported similar levels of efficacy for a variety of episode parameters (frequency, duration, number of emesis, nausea severity). There was a 50% reduction in at least one of those four parameters in 72% of subjects treated with amitriptyline and 68% of subjects treated Co-Q. However, while no side effects were reported on Co-Q, 50% of subjects on amitriptyline reported side effects (P = 5 × 10(-7)), resulting in 21% discontinuing treatment (P = 0.007). Subjects/parents considered the benefits to outweigh the risks of treatment in 47% of cases on amitriptyline and 77% of cases on Co-Q (P = 0.008). CONCLUSION: Our data suggest that the natural food supplement Co-Q is potentially efficacious and tolerable in the treatment of CVS, and should be considered as an option in CVS prophylaxis. Our data would likely be helpful in the design of a double-blind clinical trial. |
format | Text |
id | pubmed-2825193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28251932010-02-20 Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study Boles, Richard G Lovett-Barr, Mary R Preston, Amy Li, B UK Adams, Kathleen BMC Neurol Research article BACKGROUND: Cyclic vomiting syndrome (CVS), which is defined by recurrent stereotypical episodes of nausea and vomiting, is a relatively-common disabling condition that is associated with migraine headache and mitochondrial dysfunction. Co-enzyme Q10 (Co-Q) is a nutritional supplement that has demonstrated efficacy in pediatric and adult migraine. It is increasingly used in CVS despite the complete lack of studies to demonstrate its value in treatment METHODS: Using an Internet-based survey filled out by subjects with CVS or their parents, the efficacy, tolerability and subject satisfaction in CVS prophylaxis were queried. Subjects taking Co-Q (22 subjects) were compared against those taking amitriptyline (162 subjects), which is the general standard-of-care. RESULTS: Subjects/parents reported similar levels of efficacy for a variety of episode parameters (frequency, duration, number of emesis, nausea severity). There was a 50% reduction in at least one of those four parameters in 72% of subjects treated with amitriptyline and 68% of subjects treated Co-Q. However, while no side effects were reported on Co-Q, 50% of subjects on amitriptyline reported side effects (P = 5 × 10(-7)), resulting in 21% discontinuing treatment (P = 0.007). Subjects/parents considered the benefits to outweigh the risks of treatment in 47% of cases on amitriptyline and 77% of cases on Co-Q (P = 0.008). CONCLUSION: Our data suggest that the natural food supplement Co-Q is potentially efficacious and tolerable in the treatment of CVS, and should be considered as an option in CVS prophylaxis. Our data would likely be helpful in the design of a double-blind clinical trial. BioMed Central 2010-01-28 /pmc/articles/PMC2825193/ /pubmed/20109231 http://dx.doi.org/10.1186/1471-2377-10-10 Text en Copyright ©2010 Boles et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research article Boles, Richard G Lovett-Barr, Mary R Preston, Amy Li, B UK Adams, Kathleen Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study |
title | Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study |
title_full | Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study |
title_fullStr | Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study |
title_full_unstemmed | Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study |
title_short | Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study |
title_sort | treatment of cyclic vomiting syndrome with co-enzyme q10 and amitriptyline, a retrospective study |
topic | Research article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825193/ https://www.ncbi.nlm.nih.gov/pubmed/20109231 http://dx.doi.org/10.1186/1471-2377-10-10 |
work_keys_str_mv | AT bolesrichardg treatmentofcyclicvomitingsyndromewithcoenzymeq10andamitriptylinearetrospectivestudy AT lovettbarrmaryr treatmentofcyclicvomitingsyndromewithcoenzymeq10andamitriptylinearetrospectivestudy AT prestonamy treatmentofcyclicvomitingsyndromewithcoenzymeq10andamitriptylinearetrospectivestudy AT libuk treatmentofcyclicvomitingsyndromewithcoenzymeq10andamitriptylinearetrospectivestudy AT adamskathleen treatmentofcyclicvomitingsyndromewithcoenzymeq10andamitriptylinearetrospectivestudy |